Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Investigating the outcomes of children born to patients with CML

Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, presents an overview of the outcomes of children in the GIMEMA registry who were born to female chronic myeloid leukemia (CML) patients or to partners of male CML patients. This work aimed to elucidate any effects that the disease or the drugs taken before conception/during pregnancy may have on fertility, gestation, pre-natal development of the fetus, and the post-natal growth and development of the child. No significant problems were identified in these children, indicating that it is feasible for patients with CML to start a family. Oocyte harvest as part of the in vitro fertilization (IVF) also did not appear to be jeopardized by CML treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultancy: Takeda, Pfizer, Novartis, Incyte, BMS
Membership on Board of Directors or Advisory Committee: Novartis, Incyte, BMS